Document Detail

A randomized invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter.
MedLine Citation:
PMID:  20588189     Owner:  NLM     Status:  In-Process    
BACKGROUND: This study assessed the cardiac electrophysiological and hemodynamic effects of an intravenous infusion of the combined ion channel blocker AZD1305.
METHODS: After successful ablation of atrial flutter, patients were randomized to receive placebo (n = 12) or AZD1305 (n = 38) in 4 ascending dose groups. Electrophysiological and hemodynamic measurements were performed before and commencing 20 minutes after start of infusion.
RESULTS: Left atrial effective refractory period increased dose and the primary outcome measure increased dose and plasma concentration dependently, with a mean increase of 55 milliseconds in dose group 3. There was a corresponding increase in right atrial effective refractory period of 84 milliseconds. The right ventricular effective refractory period and the paced QT interval also increased dose and concentration dependently, by 59 and 70 milliseconds, respectively, in dose group 3. There were indications of moderate increases of atrial, atrioventricular nodal, and ventricular conduction times. No consistent changes in intracardiac pressures were observed, but there was a small transient decrease in systolic blood pressure. Adverse events were consistent with the study population and procedure, and there were no signs of proarrhythmia despite marked delay in ventricular repolarization in some individuals.
CONCLUSIONS: AZD1305 shows electrophysiological characteristics indicative of potential antiarrhythmic efficacy in atrial fibrillation.
Lauri Toivonen; Pekka Raatikainen; Håkan Walfridsson; Anders Englund; Finn Hegbom; Ole-Gunnar Anfinsen; Knut Gjesdal; Steen Pehrson; Susanne Johansson; Lars Frison; Anders R Berggren; Nils Edvardsson
Related Documents :
2254549 - Demonstration of an area of slow conduction in human atrial flutter.
8682029 - Effect of flecainide on atrial and ventricular refractoriness and conduction in patient...
836739 - Bradycardia-dependent interatrial block with retrograde left atrial activation.
9584299 - Is the atrial high rate episode diagnostic feature reliable in detecting paroxysmal epi...
6377969 - The local expression of adult chicken heart myosins during development. i. the three da...
77889 - Concealed atrial bigeminy and trigeminy.
3788219 - The characteristics of acute renal failure in cardiogenic shock in the elderly.
8466239 - Cardiac rhabdomyomas and their association with tuberous sclerosis.
17566079 - Cardiac mass and cardiomyocyte size are governed by different genetic loci on either au...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  56     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  300-8     Citation Subset:  IM    
Department of Cardiology, University Central Hospital, Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transi...
Next Document:  Congestive heart failure: where homeostasis begets dyshomeostasis.